# Regenerative Breast Scaffolds

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/regenerative-breast-scaffolds
Canonical HTML page: https://gethealthbrief.com/entity/regenerative-breast-scaffolds

## Timeline

- **2026-06-30**: 30-patient milestone announced — BellaSeno reports that 30 women have now been treated (19 from the initial study + 11 in the pivotal trial) and highlights progress toward global market entry.
- **2026-05**: Two-year outcomes presented at The Aesthetic MEET 2026 — Professor Anand Deva presents two-year follow-up data showing no scaffold-related complications and 83% mean breast volume retention.
- **2026-01**: Pivotal clinical trial launched — BellaSeno starts its pivotal trial in Australia to gather evidence for broader regulatory approval and global commercialization.
- **2023**: Initial study enrollment completes — The 19-patient first-in-human safety cohort is fully enrolled; patients are followed for two years.
- **2021**: First-in-human safety study begins — BellaSeno initiates a 19-patient clinical investigation of its breast scaffolds in Australia, aimed at assessing initial safety and tissue regeneration.

## Recent coverage (1 stories)

### 83% breast volume retention reported in BellaSeno’s regenerative scaffold trial
2026-07-02 00:14:59 · Sentiment: Positive · Impact: 7/10 · Sources: 3

BellaSeno announced two-year follow-up data from its first-in-human breast scaffold trial, showing an 83% mean volume retention and zero scaffold-related complications in 19 patients. An additional 11 patients are enrolled in a pivotal Australian trial, with global commercialization as the next goal.
Full story: https://gethealthbrief.com/story/bellaseno-regenerative-scaffolds-83-percent-volume-retention

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.